Abstract: |
Although cutaneous and uveal melanoma share several features, including a cell of origin, they show significant differences on an epidemiological, molecular, and genetic level which affect their evolution. Melanoma patients rarely present with metastatic disease from the beginning and often develop metastatic disease years later. The presence of liver metastases significantly diminishes survival of melanoma patients, and surgical resection of liver metastases has been shown to improve overall survival, when feasible. However, the majority of patients are not surgical candidates, and therefore, less invasive treatment options have been studied to address the liver metastases based on experience from other cancers, such as hepatocellular carcinoma and colorectal cancer. Interventional oncology plays a significant role in the management of patients with metastatic uveal melanoma, starting from the diagnosis of metastatic disease through image-guided biopsies, moving to the different locoregional treatment options offered to patients with differing burdens of liver metastases. Immunotherapy has changed the management of metastatic melanoma over the past decade, and combination therapies involving locoregional interventional oncologic treatments and immunotherapy are anticipated to provide improved outcomes for this patient population. © Springer Nature Switzerland AG 2020. |